首页> 外文期刊>Journal of Clinical Oncology >Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
【24h】

Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.

机译:三联疗法结合诱导化疗,然后行胸膜外肺切除术和辅助大剂量半胸腔放疗治疗恶性胸膜间皮瘤。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: Malignant pleural mesothelioma (MPM) remains associated with poor outcome. We examined the results of trimodality therapy with cisplatin-based chemotherapy followed by extrapleural pneumonectomy (EPP) and adjuvant high-dose (50 to 60 Gy) hemithoracic radiation therapy for MPM. PATIENTS AND METHODS: We conducted a retrospective review of all patients prospectively evaluated for trimodality therapy protocol between January 2001 and December 2007 in our institution. RESULTS: A total of 60 patients were suitable candidates. Histology was epithelioid (n = 44) or biphasic (n = 16). Chemotherapy regimens included cisplatin/vinorelbine (n = 26), cisplatin/pemetrexed (n = 24), cisplatin/raltitrexed (n = 6), or cisplatin/gemcitabine (n = 4). EPP was performed in 45 patients, and hemithoracic radiation therapy to at least 50 Gy was administered postoperatively to 30 patients. Completion of the trimodality therapy in the absence of mediastinal node involvement was associated with the best survival (mediansurvival of 59 months v
机译:目的:恶性胸膜间皮瘤(MPM)仍与不良预后相关。我们研究了以顺铂为基础的化学疗法,胸膜外肺切除术(EPP)和高剂量(50至60 Gy)辅助半乳糖放射治疗MPM的三联疗法的结果。病人与方法:我们对我院2001年1月至2007年12月间所有接受三联疗法治疗方案评估的患者进行了回顾性研究。结果:总共60例患者是合适的候选人。组织学为上皮样(n = 44)或双相性(n = 16)。化疗方案包括顺铂/长春瑞滨(n = 26),顺铂/培美曲塞(n = 24),顺铂/雷替曲塞(n = 6)或顺铂/吉西他滨(n = 4)。 EPP在45例患者中进行,术后对30例患者进行了至少50 Gy的半胸腔放射治疗。在没有纵隔淋巴结受累的情况下完成三联疗法与最佳生存期相关(其余患者的中位生存期为59个月v≤14个月,P = .0003)。诱导化疗的类型对生存期无明显影响。尽管完成了三联疗法,病理结节状态仍是存活率低的重要预测指标。协议完成后,N0疾病患者的5年无病生存率为53%,ypT1-2N0患者达到75%,ypT3-4N0患者达到45%。结论:在诱导化疗,EPP和辅助大剂量半胸腔放疗进行MPM方面的大量单中心经验表明,一半的患者能够完成此方案。对于N0病患者而言,结果令人鼓舞。然而,尽管完成了全部三联疗法,N2疾病仍然是影响生存的主要因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号